Clinical trial NCT03889951: Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy
Official title: Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: ALL, Childhood
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-03-26
Enrollment: 50
Sex: ALL
Minimum age (years): 1
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients newly diagnosed with acute lymphoblastic leukemia age ranged from 1 year to 70 years.

Brief summary: 1. To detect IKZF-1 deletion mutations in patients with ALL.
2. To study the impact of IKZF-1 deletion mutation on therapy of ALL.
3. To study the correlation between IKZF-1 deletion mutations and BCR-ABL.

Detailed description: Acute lymphoblastic leukemia (ALL) a malignant transformation and proliferation of lymphoid progenitor cells in the bone marrow, blood and extramedullary sites. While 80% of ALL occurs in children, it represents a devastating disease when it occurs in adults . predisposing factors include exposure to ionizing radiation, pesticides, certain solvents or viruses such as Epstein-Barr Virus and Human Immunodeficiency Virus. However, in the majority of cases, it appears as a de novo malignancy in previously healthy individuals. Chromosomal aberrations are the hallmark of ALL, but are not sufficient to generate leukemia. Characteristic translocations include t(12;21) \[ETV6-RUNX1\], t(1;19) \[TCF3-PBX1\], t(9;22) \[BCR-ABL1\] . More recently, a variant with a similar gene expression profile to (Philadelphia) Ph-positive ALL but without the BCR-ABL1 rearrangement has been identified. In more than 80% of cases of this so-called Ph-like ALL, the variant possesses deletions in key transcription factors involved in B-cell development including IKAROS family zinc finger 1 (IKZF1) . IKZF1 codes Ikaros, which is a member of a family of zinc- finger nuclear proteins that is required for the earliest stages of lymphoid lineage commitment and acts as tumor suppressor. Most IKZF1 mutations (94%) are deletion mutations, and there are rare point mutations resulting in loss of function of Ikaros .

There are two major deletions occur in the IKZF1 gene:

* The first one was characterized by loss of exons 4 to 7 ( 4-7) with breakpoints occurring in introns 3 and 7 on chromosome 7p12.
* The second deletion involved exons 2 to 7 ( 2-7) with a variable pattern of breakpoints in intron 1 and intron 7 in the same region as those of the 4-7 deletion.

IKZF1 mutations in cases of B-ALL are associated with poor prognosis and high risk of relapse. IKZF1 mutations are found in approximately 15% to 20% of pediatric B-ALL cases and in \>75% of pediatric BCR-ABL positive ALL cases. The incidences of IKZF1 mutations in adults are approximately 50% in B-ALL cases and approximately 65% in BCR-ABL positive ALL cases .

The presence of either IKZF1 mutation or BCR- ABL has been reported to be an independent risk factor of poor prognosis for patients with B-ALL .

Eligibility criteria: Inclusion Criteria:

* Patients with acute lymphoblastic leukemia.

Exclusion Criteria:

* patients with any other hematological malignancies.
* patients receiving chemotherapy.

Primary outcomes:
measure: detection of IKZF-1 deletion mutations in patients with ALL.
timeFrame: baseline
measure: Detection of BCR-ABL translocation.
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: